US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
2 deals · US$155mdisclosed · Ophthalmology · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Apr 2026 | Opus Genetics | – | – | Placement | Announced | 5.0 | Biotech+1 | Sidley Austin (issuer) |
| Feb 2026 | SpyGlass Pharma | – | – | IPO | Announced | 150.0 | Ophthalmology+1 | Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Stifel (lead manager)Latham & Watkins (lead manager) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built